Claire Louise Newton

Dr. Claire Louise Newton

University of Pretoria, Pretoria, Gauteng, South Africa
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
JGJ. T. George
J. T. George
JVJ. D. Veldhuis
J. D. Veldhuis
ARA. K. Roseweir
A. K. Roseweir
Claire Louise NewtonClaire Louise Newton
Claire Louise Newton
EFE. Faccenda
E. Faccenda
RAR. A. Anderson
R. A. Anderson
Context: Kisspeptins stimulate GnRH and thus gonadotropin secretion. Kisspeptin-10 is the minimal kisspeptin sequence with full intrinsic bioactivity, but it has not been studied in man. Objective: We investigated our hypothesis that kisspeptin-10 increases GnRH and thus LH pulse frequency. Design and Participants: The dose response of kisspeptin-10 was investigated by administering iv bolus doses (0.01–3.0 μg/kg) and vehicle to healthy men. Effects on LH pulse frequency and size were determined by deconvolution analysis during infusion of kisspeptin-10 for up to 22.5 h. Results: Intravenous bolus kisspeptin-10 resulted in a rapid and dose-dependent rise in serum LH concentration, with maximal stimulation at 1 μg/kg (4.1 ± 0.4 to 12.4 ± 1.7 IU/liter at 30 min, P < 0.001, n = 6). Administration of 3 μg/kg elicited a reduced response vs. 1 μg/kg (P < 0.05). Infusion of kisspeptin-10 at 4 μg/kg · h for 22.5 h elicited an increase in LH from a mean of 5.4 ± 0.7 to 20.8 ± 4.9 IU/liter (n = 4; P < 0.05) and serum testosterone increased from 16.6 ± 2.4 to 24.0 ± 2.5 nmol/liter (P < 0.001). LH pulses were obscured at this high rate of secretion, but a lower dose infusion of kisspeptin-10 (1.5 μg/kg · h) increased mean LH from 5.2 ± 0.8 to 14.1 ± 1.7 IU/liter (n = 4; P < 0.01) and increased LH pulse frequency from 0.7 ± 0.1 to 1.0 ± 0.2 pulses/h (P < 0.05) and secretory burst mass from 3.9 ± 0.4 to 12.8 ± 2.6 IU/liter (P < 0.05). Conclusions: Kisspeptin-10 boluses potently evoke LH secretion in men, and continuous infusion increases testosterone, LH pulse frequency, and pulse size. Kisspeptin analogues have therapeutic potential as regulators of LH and thus testosterone secretion.

1 January 2010 in Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
RMRobert Millar
Robert Millar
Claire Louise NewtonClaire Louise Newton
Claire Louise Newton
I (R.P.M.) presented “The Year In G Protein-Coupled Receptor Research” at ENDO 2009. I first described the diversity of ligands and the five families into which the approximately 800 G protein-coupled receptors (GPCRs) are grouped, their basic structural architectures, their preeminent role in signaling, and the enormous scope for developing drugs targeted at GPCRs. I then spoke about some of the exciting breakthroughs in solving the atomic level structures of the active state of rhodopsin, β2-adrenergic, β1-adrenergic, and A2A-adenosine receptors. I also described studies on the structural changes accompanying the activation of the rhodopsin family of GPCRs. From these recent technical advances, we can anticipate that many more GPCR structures will emerge, which will afford us greater insight into their common and unique structural features and, particularly, the mechanisms underlying their activation. These insights will guide us in our understanding of how GPCRs operate, both in the normal and pathological situation. Although these crystal structures are highly informative, it is important to recognize that they represent static frozen conformations of a single GPCR state. New biophysical techniques are therefore being utilized to facilitate the dynamic monitoring of GPCR structural changes in relation to ligand activation. Solving of the crystal structures of GPCRs has also presented the real possibility of using the information of the ligand-binding pocket to allow in silico screening for novel small-molecule ligands. I then reviewed the concept of ligand-induced selective signaling of GPCRs, which is opening up new insights into more selective drug development. The assembly of GPCRs as homo- and heterooligomers and their phosphorylation and association with a vast array of trafficking and signal-modulating proteins are emerging as major mechanisms underlying the functioning of GPCRs. Differential expression and recruitment of these proteins provide a mechanism for subtle physiological regulation of cellular activity. Finally, I mentioned some of the GPCRs that have lately come to the fore as novel regulators in endocrinology. These included fatty acid-specific GPCRs expressed in pancreatic β-cells and novel neuroendocrine GPCRs regulating reproduction.

2 July 2013 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
RMRobert Millar
Robert Millar
Claire Louise NewtonClaire Louise Newton
Claire Louise Newton

11 April 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
Claire Louise NewtonClaire Louise Newton
Claire Louise Newton
AWAdele M. Whay
Adele M. Whay
CMCraig A. McArdle
Craig A. McArdle
MZMeilin Zhang
Meilin Zhang
CKChris J. van Koppen
Chris J. van Koppen
RMRobert Millar
Robert Millar
Naturally occurring mutations of G protein-coupled receptors (GPCRs) causing misfolding and failure to traffic to the cell surface can result in disease states. Some small-molecule orthosteric ligands can rescue such misfolded receptors, presumably by facilitating their correct folding and shuttling to the plasma membrane. Here we show that a cell-permeant, allosterically binding small-molecule agonist (Org 42599) rescues the folding and cell surface expression, and therefore target cell signaling, of mutant human luteinizing hormone (LH) receptors (A593P and S616Y) that cause Leydig cell hypoplasia in man. Both mutant receptors were retained in the cytoplasm whereas WT receptor localized at the cell membrane, and binding of LH to cells expressing the mutant receptors was markedly lower than to those expressing the WT receptor. Incubation with Org 42599 increased mutant receptor expression, cell surface localization, and the proportion of mutant receptor in the mature glycosylated form. Importantly, although LH stimulated little (S616Y) or no (A593P) activation of cells expressing mutant receptors, incubation of cells with Org 42599 facilitated rescue of expression and stimulation by the native ligand, LH. Although Org 42599 could activate these receptors, it could not displace 125I-labeled human LH binding to the WT receptor, indicating that it acts in an allosteric manner. Here we demonstrate a small-molecule GPCR allosteric agonist that functionally rescues intracellularly retained mutant LH receptors by facilitating their cell surface expression. This approach may have application for treatment of infertile patients bearing such mutations and, more broadly, for other misfolded GPCR mutants resulting in human pathologic processes.

2 July 2018 in Endocrine Reviews
Verified
Journal Article
Closed access
PDF file
RARoss Calley Anderson
Ross Calley Anderson
Claire Louise NewtonClaire Louise Newton
Claire Louise Newton
RARichard A Anderson
Richard A Anderson
RMRobert Millar
Robert Millar
The gonadotropin receptors, luteinising hormone receptor, and follicle-stimulating hormone receptor, play a central role in governing reproductive competency/fertility. Gonadotropin hormone analogues have been utilised clinically for decades, in assisted reproductive therapies, and in the treatment of various infertility disorders. While these treatments are effective, the clinical protocols demand multiple injections, and the hormone preparations can lack uniformity and stability. The past two decades have seen a drive to develop chimeric and modified peptide analogues with more desirable pharmacokinetic profiles with some displaying clinical efficacy, such as corifollitropin alfa which is now in clinical use. More recently, low molecular weight orally-active molecules with activity at gonadotropin receptors have been developed. Some have excellent characteristics in animals and in human studies but have not reached the market: largely due to acquisitions by large pharma. Nonetheless such molecules have the potential to mitigate risks currently associated with gonadotropin-based fertility treatments such as ovarian hyperstimulation syndrome and the demands of injection-based therapies. There is also scope for novel utilisation beyond the current remit of gonadotropin analogues in fertility treatments, including application as novel contraceptives, and in the treatment of polycystic ovary syndrome, the restoration of function to inactivating mutations of gonadotropin receptors, ovarian and prostate cancers, and in bone loss and weight gain in postmenopausal women. Here, we review the properties and clinical application of current gonadotropin preparations and their analogues, as well as the development of novel orally-active small-molecule non-peptide analogues.

17 August 2016 in Endocrinology
Verified
Journal Article
Closed access
Claire Louise NewtonClaire Louise Newton
Claire Louise Newton
RARoss Calley Anderson
Ross Calley Anderson
AKArieh Anthony Katz
Arieh Anthony Katz
RMRobert Millar
Robert Millar
Mutations in G protein–coupled receptors (GPCRs) have been identified for many endocrine hormone signaling deficiencies. Inactivating mutations can impair ligand binding, receptor activation/coupling to signaling pathways, or can cause receptor misfolding and consequent impaired expression at the cell membrane. Here we examine the cell surface expression, ligand binding, and signaling of a range of mutant human luteinizing hormone receptors (LHRs) identified as causing reproductive dysfunction in human patients. The data obtained reveal how mutations in GPCRs can have diverse and severely deleterious effects on receptor function. Furthermore, it was found that impaired functionality of the majority of the mutant LHRs was due to reduced expression at the cell surface (14/20) while only two mutations caused impaired binding affinity and two impaired in signaling. An additional two mutations were found to cause no impairment of receptor function. These data demonstrate that the majority of LHR mutations lead to intracellular retention and highlight the potential for novel pharmacological chaperone therapeutics that can “rescue” expression/function of retained mutant GPCRs.